Bradykinin receptors and their antagonists

Area of Science:

• Pharmacology and Molecular Biology
• Receptor research
• Drug discovery

Background:

• Bradykinin and related kinins mediate physiological effects through B1 and B2 receptors.
• Classical bioassays and modern molecular techniques have been used to characterize these receptors.
• Previous antagonists showed limitations, including partial agonism and lack of selectivity.

Purpose of the Study:

• To classify bradykinin receptors (B1 and B2) using established criteria.
• To evaluate the efficacy and selectivity of novel B1 and B2 receptor antagonists.
• To assess the potential of these antagonists in pharmacological and clinical applications.

Main Methods:

• Receptor classification based on agonist potency and antagonist affinity.
• Binding assays using cell membranes expressing native or transfected human kinin receptors.
• Evaluation of peptide and non-peptide antagonists, including their metabolic stability and selectivity.

Main Results:

• Second-generation antagonists like HOE 140 are long-acting, selective for B2 receptors, and effective in vivo.
• Emerging non-peptide B2 antagonists, such as FR 173657, show oral activity and broad species specificity.
• Improved B1 antagonists (R 715, B 9958) are pure antagonists in certain species, resistant to degradation, and have reduced residual agonistic activity.

Conclusions:

• Advancements in antagonist development have led to highly selective and potent compounds for both B1 and B2 receptors.
• Newer antagonists overcome limitations of earlier compounds, enabling more precise pharmacological studies.
• These developments hold promise for future therapeutic strategies targeting the kinin system.